Idiopathic membranous nephropathy: Diagnosis and treatment

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 905-919

  Fervenza, Fernando C ^a   Sethi, Sanjeev ^a   Specks, Ulrich ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ALGORITHM; ARTICLE; BIOPSY; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG COMBINATION; GLOMERULUS; HUMAN; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PATHOLOGY; PATIENT SELECTION; PROTEINURIA; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; DIURETICS; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; MALE; PATIENT SELECTION; PROTEINURIA; TREATMENT OUTCOME;

EID: 44649177183     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04321007     Document Type: Conference Paper

References (118)

1. Markowitz GS: Membranous glomerulopathy: Emphasis on secondary forms and disease variants. Adv Anat Pathol 8: 119-125, 2001
2. Noel LH, Zanetti M, Droz D, Barbanel C: Long-term prognosis of idiopathic membranous glomerulonephritis: Study of 116 untreated patients. Am J Med 66: 82-90, 1979
3. Zucchelli P, Ponticelli C, Cagnoli L, Passerini P: Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2: 73-78, 1987
4. Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner HV: Long-term prognosis of chronic idiopathic membranous glomerulonephritis: An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 31: 67-76, 1989
5. Marx BE, Marx M: Prediction in idiopathic membranous nephropathy. Kidney Int 56: 666-673, 1999
6. Gluck MC, Gallo G, Lowenstein J, Baldwin DS: Membranous glomerulonephritis: Evolution of clinical and pathologic features. Ann Intern Med 78: 1-12, 1973
7. Yoshimoto K, Yokoyama H, Wada T, Furuichi K, Sakai N, Iwata Y, Goshima S, Kida H: Pathologic findings of initial biopsies reflect the outcomes of membranous nephropathy. Kidney Int 65: 148-153, 2004
8. Troyanov S, Roasio L, Pandes M, Herzenberg AM, Cattran DC: Renal pathology in idiopathic membranous nephropathy: A new perspective. Kidney Int 69: 1641-1648, 2006
9. Swaminathan SL, Melton LJ III, Bergstralh EJ, Leung N, Fervenza FC: Changing incidence of glomerular disease in the Olmstead County: A 30-year renal biopsy study. Clin J Am Soc Nephrol 1: 483-487, 2006
10. Haas M, Meehan SM, Karrison TG, Spargo BH: Changing etiologies of unexplained adult nephrotic syndrome: A comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 30: 621-631, 1997
11. Glassock RJ: Secondary membranous glomerulonephritis. Nephrol Dial Transplant 7[Suppl 1]: 64-71, 1992
12. Cattran DC: Idiopathic membranous glomerulonephritis. Kidney Int 59: 1983-1994, 2001
13. Couser WG, Shankland SJ: Membranous nephropathy. In: Comprehensive Clinical Nephrology, 2nd Ed., edited by Johnson RJ, Feehally J, Philadelphia, Elsevier, 2003, pp 295-307
14. Donadio JV Jr, Torres VE, Velosa JA, Wagoner RD, Holley KE, Okamura M, Ilstrup DM, Chu CP: Idiopathic membranous nephropathy: The natural history of untreated patients. Kidney Int 33: 708-715, 1988
15. Troyanov SW, Cattran DC: Natural history of patients with idiopathic membranous nephropathy (IMGN) who never become nephrotic [Abstract]. J Am Soc Nephrol 14: 287A, 2003
16. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
17. du Buf-Vereijken PW, Branten AJ, Wetzels JF: Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis 46: 1012-1029, 2005
18. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P: Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am J Kidney Dis 35: 157-165, 2000
19. Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol 16: 1188-1194, 2005
20. Glassock RJ: The treatment of idiopathic membranous nephropathy: A dilemma or a conundrum? Am J Kidney Dis 44: 562-566, 2004
21. Reichert LJ, Koene RA, Wetzels JF: Urinary IgG excretion as a prognostic factor in idiopathic membranous nephropathy. Clin Nephrol 48: 79-84, 1997
22. Reichert LJ, Koene RA, Wetzels JF: Urinary excretion of beta 2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J Am Soc Nephrol 6: 1666-1669, 1995
23. Branten AJ, du Buf-Vereijken PW, Klasen IS, Bosch FH, Feith GW, Hollander DA, Wetzels JF: Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: A validation study. J Am Soc Nephrol 16: 169-174, 2005
24. Bakoush O, Torffvit O, Rippe B, Tencer J: Renal function in proteinuric glomerular diseases correlates to the changes in urine IgM excretion but not to the changes in the degree of albuminuria. Clin Nephrol 59: 345-352, 2003
25. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, Pisano L, D'Amico G: Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis 38: 240-248, 2001
26. Pei Y, Cattran D, Greenwood C: Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966, 1992
27. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
28. Troyanov SW, Miller JA, Scholey JW, Cattran DC: Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66: 1199-1205, 2004
29. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995
30. Giordano M, De Feo P, Lucidi P, DePascale E, Giordano G, Cirillo D, Dardo G, Signorelli SS, Castellino P: Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int 60: 235-242, 2001
31. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, Group AS: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis. Ann Intern Med 139: 244-252, 2003
32. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 45: S174-S178, 1994
33. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 45: S145-S149, 1994
34. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R, RENAAL Study Investigators: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63: 1499-1507, 2003
35. Gansevoort RT, Heeg JE, Vriesendorp R, de Zeeuw D, de Jong PE: Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy. Nephrol Dial Transplant 7[Suppl 1]: 91-96, 1992
36. Ruggenenti P, Mosconi L, Vendramin G, Moriggi M, Remuzzi A, Sangalli F, Remuzzi G: ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. Am J Kidney Dis 35: 381-391, 2000
37. Ambalavanan S, Fauvel JP, Sibley RK, Myers BD: Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 7: 290-298, 1996
38. Rostoker G, Ben Maadi A, Remy P, Lang P, Lagrue G, Weil B: Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: A prospective study of long-term treatment. Nephrol Dial Transplant 10: 25-29, 1995
39. Praga M, Borstein B, Andres A, Arenas J, Oliet A, Montoyo C, Ruilope LM, Rodicio JL: Nephrotic proteinuria without hypoalbuminemia: Clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 17: 330-338, 1991
40. Praga M, Hernandez E, Montoyo C, Andres A, Ruilope LM, Rodicio JL: Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248, 1992
41. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260-269, 2001
42. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
43. Perna A, Schieppati A, Zamora J, Giuliano GA, Braun N, Remuzzi G: Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. Am J Kidney Dis 44: 385-401, 2004
44. Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S: A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320: 210-215, 1989
45. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B: A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13, 1989
46. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600-1604, 1995
47. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
48. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899-1904, 2007
49. Ponticelli C, Zucchelli P, Passerini P, Cesana B: Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 327: 599-603, 1992
50. Faurschou M, Sorensen IJ, Mellemkjaer L, Loft AG, Thomsen BS, Tvede N, Baslund B: Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100-105, 2008
51. Balow JE, Austin HA 3rd, Tsokos GC, Antonovych TT, Steinberg AD, Klippel JH: NIH conference: Lupus nephritis. Ann Intern Med 106: 79 -94, 1987
52. Koyama H, Wada T, Nishizawa Y, Iwanaga. T, Aoki Y: Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409,1977
53. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL, North America Nephrotic Syndrome Study Group: Cyclosporine in patients with steroid-resistant membranous nephropathy: A randomized trial. Kidney Int 59: 1484-1490, 2001
54. Meyrier A, Noel LH, Auriche P, Callard P: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 45: 1446-1456, 1994
55. Alexopoulos E, Papagianni A, Tsamelashvili M, Leontsini M, Memmos D: Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 21: 3127-3132, 2006
56. Praga M, Barrio V, Juarez GF, Luno J: Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 71: 924-930, 2007
57. Cameron JS, Healy MJ, Adu D: The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 74: 133-156, 1990
58. Donadio JV Jr, Holley KE, Anderson CF, Taylor WF: Controlled trial of cyclophosphamide in idiopathic membranous nephropathy. Kidney Int 6: 431-439, 1974
59. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P, Grassi C, Limido D, Pasquali S, Volpini T: Controlled trial of methytprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946-950, 1984
60. Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS: Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 37: 229-234, 1992
61. West ML, Jindal KK, Bear RA, Goldstein MB: A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int 32: 579-584, 1987
62. Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ: Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 2: 869-872, 1988
63. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission of membranous glomerulonephritis after cyclophosphamide and prednisone. Ann Intern Med 114: 725-730, 1991
64. Falk RJ, Hogan SL, Muller KE, Jennette JC: Treatment of progressive membranous glomerulopathy: A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med 116: 438-445, 1992
65. Jindal K, West M, Bear R, Goldstein M: Long-term benefits of therapy with cyclophosphamide and prednisone in patients with membranous glomerulonephritis and impaired renal function. Am J Kidney Dis 19: 61-67, 1992
66. Warwick GL, Geddes CG, Boulton-Jones JM: Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 87: 223-229, 1994
67. Branten AJ, Reichert LJ, Koene RA, Wetzels JF: Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91: 359-366, 1998
68. Torres A, Dominguez-Gil B, Carreno A, Hernandez E, Morales E, Segura J, Gonzalez E, Praga M: Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 61: 219-227, 2002
69. du Buf-Vereijken PW, Branten AJ, Wetzels JF: Cytotoxic therapy for membranous nephropathy and renal insufficiency: Improved renal survival but high relapse rate. Nephrol Dial Transplant 19: 1142-1148, 2004
70. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47: 1130 -1135, 1995
71. Miller G, Zimmerman R 3rd, Radhakrishnan J, Appel G: Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 36: 250-256, 2000
72. Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, Briggs WA: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61: 1098-1114, 2002
73. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248-256, 2007
74. Berg AL, Arnadottir M: ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 19: 1305-1307, 2004
75. Berg AL, Nilsson-Ehle P, Arnadottir M: Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 56: 1534-1543, 1999
76. Ponticelli C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P: A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47: 233-240, 2006
77. Kerjaschki D, Neale TJ: Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 7: 2518-2526, 1996
78. Cupps TR, Edgar LC, Fauci AS: Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 128: 2453-2457, 1982
79. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA: Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7: 711-717, 1988
80. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
81. Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G: Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851-1857, 2003
82. Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, Leung N, Cohen IM, Wochos DN, Bergstralh E, Hladunewich M, Cattran DC: Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117-125, 2008
83. Ruggenenti P, Chiurchiu C, Abbate M, Perna A, Cradevi P, Bontempelli M, Remuzzi G: Rituximab for idiopathic membranous nephropathy: Who can benefit? Clin J Am Soc Nephrol 1: 738-748, 2006
84. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, et al.: Nomenclature of systemic vasculitides: Proposal of an international consensus conference. Arthritis Rheum 37: 187-192, 1994
85. Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U: ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 120: 643 e649-e614, 2007
86. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B: Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum 42: 421-430, 1999
87. Keogh KA, Specks U: Churg-Strauss syndrome: Clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115: 284-290, 2003
88. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76-85, 1983
89. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498, 1992
90. Martin F, Chan AC: Pathogenic roles of B cells in human autoimmunity: Insights from the clinic. Immunity 20: 517-527, 2004
91. Huugen D, Tervaert JW, Heeringa P: Antineutrophil cytoplasmic autoantibodies and pathophysiology: New insights from animal models. Curr Opin Rheumatol 16: 4-8, 2004
92. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44: 2836-2840, 2001
93. Keogh KA, Wylam ME, Stone JH, Specks U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268, 2005
94. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U: Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173: 180-187, 2006
95. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, Morimoto S, Kaneda K, Kobayashi S, Hashimoto H, Takasaki Y: Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 46: 409-414, 2007
96. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D: Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 45: 1432-1436, 2006
97. Ferraro AJ, Day Cj, Drayson MT, Savage CO: Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 20: 622-625, 2005
98. Eriksson P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257: 540-548, 2005
99. Maher LV, Wilson JG: Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 45: 1450-1451, 2006
100. Koukoulaki M, Smith KG, Jayne DR: Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 65: 557-559, 2006
101. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, Lamprecht P, Gross WL: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65: 853-858, 2006
102. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: Favourable but temporary response. Scand J Rheumatol 34: 229-232, 2005
103. Seo P, Specks U, Keogh K: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations [Abstract]. Clin Exp Rheumatol 25: S-111, 2007
104. Walsh M, Jayne D: Rituximab in the treatment of antineutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: Past, present and future. Kidney Int 72: 676-682, 2007
105. Cambridge G, Leandro MJ, Teodorescu, M, Manson J, Rahman A, Isenberg DA, Edwards JC: B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 54: 3612-3622, 2006
106. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350: 2572-2581, 2004
107. Smith KG, Jones RB, Burns SM, Jayne DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythernatosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 54: 2970-2982, 2006
108. Hauser AE, Muehlinghaus G, Manz RA, Cassese G, Arce S, Debes GF, Hamann A, Berek C, Lindenau S, Doerner T, Hiepe F, Odendahl M, Riemekasten G, Krenn V, Radbruch A: Long-lived plasma cells in immunity and inflammation. Ann N Y Acad Sci 987: 266-269, 2003
109. Golbin JM, Keogh KA, Fervenza FC, Ytterberg SR, Specks U: Update on rituximab use in patients with chronically relapsing Wegener's granulomatosis [Abstract]. Clin Exp Rheumatol 25: S-111, 2007
110. Rituxan warning. FDA Consum 41: 3, 2007
111. Choy DS, Weiss A, Lin PT: Progressive multifocal leukoen-cephalopathy following treatment for Wegener's granulomatosis. JAMA 268: 600-601, 1992
112. Itoh K, Kano T, Nagashio C, Mimori A, Kinoshita M, Sumiya M: Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 54: 1020-1022, 2006
113. Davis TA, Grillo-Lopez AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18: 3135-3143, 2000
114. Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr: Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol 98: 175-179, 2001
115. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I: B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589, 2004
116. Noel LH, Aucouturier P, Monteiro RC, Preud'Homme JL, Lesavre P: Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis. Clin Immunol Immunopathol 46: 186-194, 1988
117. Doi T, Mayumi M, Kanatsu K, Suehiro F, Hamashima Y: Distribution of IgG subclasses in membranous nephropathy. Clin Exp Immunol 58: 57-62, 1984
118. Bannister KM, Howarth GS, Clarkson AR, Woodroffe AJ: Glomerular IgG subclass distribution in human glomerulonephritis. Clin Nephrol 19: 161-165, 1983